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INTRODUCTION  
A drug delivery system (DDS) is defined as a 
formulation or a device that enables the introduction of a 
therapeutic substance in the body and improves its efficacy 
and safety by controlling the rate, time, and place of 
release of drugs in the body. This process includes the 
administration of the therapeutic product, the release of the 
active ingredients by the product, and the subsequent 
transport of the active ingredients across the biological 
membranes to the site of action. 
Lipid based drug delivery systems (DDS) represent a 
diverse group of formulations, each having different 
structural and functional characteristics which can be 
modified by adjusting the contents of different lipid 
excipients and other additives. The spectrum of varying 
properties seems unlimited, but is, in practice, restricted by 
cost, convenience, safety and regulatory demands. The 
introduction of new excipient combinations and DDS will 
most likely stimulate the use of lipid based DDS and lead 
to new and improved therapies in the future. Many drugs 
on the market, and in different development stages, have 
non-optimal properties that potentially could be improved 
by a suitable delivery system. 
New chemical entities (NCEs) are designed using 
increasingly available receptor structural information. 
Such chemical entities formed are polycyclic and very 
hydrophobic. About 50% of NCEs are poorly soluble and 
hence have poor bioavailability. As an oral drug delivery 
system, lipids are studied as components of various oily 
liquids and dispersions that are designed to increase 
solubility and bioavailability of drugs belonging to the 
class II and IV of the biopharmaceutical drug classification 
system
1
. Lipid carriers are equally important for 
transdermal systems as they form a protective barrier, 
make the skin water resistant, reduce the trans-epidermal 
water loss and thus protect the skin against dehydration. 
By filling up microscopic indentations in the skin they lead 
to a noticeable smoothening of the skin which 
simultaneously also reduces minor wrinkles
2
. It is also 
being proved that the unique properties of lipids viz their 
physiochemical diversity, biocompatibility which reduces 
local irritancy, make them ideal carriers for topical usage
3
.  
Increasing interests in lipid based delivery systems 
are due to following reasons like:  
 Versatility of lipidic excipients  
 Formulation versatility and the choice of different 
drug delivery systems  
 Low risk profile  
 Enhanced oral bioavailability and reduced plasma 
profile variability  
 Enhanced permeation of these systems when used 
topically  
 Formation of vesicular system which is passive, non-
invasive and is available for immediate 
commercialization.  
 Better characterization of lipidic excipients  
 High market attractiveness for products with 
proprietary technology.  
 Improved ability to address the key issues of 
technology transfer and manufacture scale up.  
DESIGN OF LIPID BASED DDS 
Several lipids based DDS have been developed over 
the years. Novel lipid drug delivery systems can be 
broadly classified as emulsions, vesicular systems and 
lipid particulate systems. 
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The word "emulsion" comes from the Latin word for 
"to milk", as milk is an emulsion of milk fat and water, 
among other components. Emulsion can be defined as 
heterogenous systems of one liquid dispersed throughout 
another in the form of droplets usually exceeding 0.1 
micrometer in diameter. Oral formulation of emulsion can 
be used in enhancing bioavailability, giving controlled rate 
of drug release, affording protection to oxidation or 
hydrolysis. Topical formulation of emulsion can be easily 
applied and formulated to eliminate oiliness and staining, 
carrying water which is an excellent softener to skin. 
Emulsion includes microemulsion, self-emulsifying 
delivery system, nanoemulsion, pickering emulsion. 
Microemulsions 
Hoar and Schulman introduced the concept of 
microemulsion in 1940. They titrated a milky type 
emulsion with hexanol to generate a single-phase clear 
solution
4
. Schulman and coworkers (1959) consequently 
coined the term of microemulsion, and it has since been 
deﬁned and indeed redeﬁned on many occasions5. 
Considering the objectives of this review, however, the 
deﬁnition provided by Danielsson and Lindman in 1981 
will be used as the point of reference
6
. Microemulsions are 
thus deﬁned as a system of water, oil and amphiphile 
which is a single optically isotropic and 
thermodynamically stable liquid solution. Microemulsions 
are readily distinguished from normal emulsions by their 
transparency, low viscosity and more fundamentally their 
thermodynamic stability. The main difference between 
emulsions and microemulsions lies in the size and shape of 
dispersed particles as microemulsions have size of smaller 
magnitude ( 10 – 200 nm) than those of conventional 
emulsions (1 – 20 μm). Also emulsions consist of roughly 
spherical droplets whereas microemulsions constantly 
evolve between various structures ranging from droplet-
like swollen micelles to bicontinuous structures
7
. 
Microemulsions have generated considerable interest 
over the years as potential drug delivery systems
8
. 
Advantages associated with microemulsions include their 
thermodynamic stability, optical clarity and ease of 
preparation. The existence of microdomains of different 
polarity within the same single-phase solution enables both 
water-soluble and oil soluble materials to be solubilised, 
and at the same time if this is so desired. Furthermore it is 
also possible to incorporate amphiphilic drugs into the 
microemulsion, sometimes even leading to an increase in 
the extent of existence of the microemulsion region
9
. 
Self emulsifying delivery systems 
Self-emulsifying drug delivery systems (SEDDS) are 
mixtures of oils and surfactants, ideally isotropic, and 
sometimes containing co-solvents, which emulsify 
spontaneously to produce fine oil-in-water emulsions when 
introduced into aqueous phase under gentle agitation
10-11
. 
Recently, SEDDS have been formulated using medium 
chain tri-glyceride oils and nonionic surfactants, the latter 
being less toxic. Upon peroral administration, these 
systems form fine emulsions (or micro-emulsions) in 
gastro-intestinal tract (GIT) with mild agitation provided 
by gastric mobility
12-13
. Potential advantages of these 
systems include enhanced oral bioavailability enabling 
reduction in dose, more consistent temporal profiles of 
drug absorption, selective targeting of drug(s) toward 
specific absorption window in GIT, and protection of 
drug(s) from the hostile environment in gut
14-15
. 
SEDDS are promising approach for oral delivery of 
poorly water-soluble compounds. It can be achieved by 
pre-dissolving the compound in a suitable solvent and fill 
the formulation into capsules. The oral drug delivery of 
hydrophobic drugs can be made possible by SEDDS. The 
main benefit of this approach is that pre-dissolving the 
compound overcomes the initial rate limiting step of 
particulate dissolution in the aqueous environment within 
the GI tract. However, a potential problem is that the drug 
may precipitate out of solution when the formulation 
disperses in the GI tract, particularly if a hydrophilic 
solvent is used (e.g. polyethylene glycol). If the drug can 
be dissolved in a lipid vehicle there is less potential for 
precipitation on dilution in the GI tract, as partitioning 
kinetics will favour the drug remaining in the lipid 
droplets
16
. 
Nanoemulsions 
Nanoemulsions are oil-in-water (o/w) emulsions with 
mean droplet diameters ranging from 50 to 1000 nm. 
Usually, the average droplet size is between 100 and 500 
nm. The particles can exist as oil-in-water and water- in-oil 
forms, where the core of the particle is either oil or water, 
respectively. Nanoemulsions are made from surfactants 
approved for human consumption and common food 
substances that are ―Generally Recognized as Safe‖ 
(GRAS) by the FDA. These emulsions are easily produced 
in large quantities by mixing a water-immiscible oil phase 
with an aqueous phase under high shear stress, or 
mechanical extrusion process that is available worldwide
17
. 
The olfactory region of the nasal mucosa provides a 
direct connection between the nose and brain, and by the 
use of nanoemulsions loaded with drugs, conditions such 
as Alzheimer‘s disease, migraine, depression, 
schizophrenia, Parkinson‘s diseases, meningitis, etc. can 
be treated
18-19
. 
Use of nanoemulsions in transdermal drug delivery 
represents an important area of research in drug delivery, 
which enhances the therapeutic efficacy and also the 
bioavailability of the drugs without any adverse effects. 
Many studies have shown that nanoemulsion formulations 
possess improved transdermal and dermal delivery 
properties in vitro
, 
as well as in vivo
20-23
. Nanoemulsions 
have improved transdermal permeation of many drugs over 
the conventional topical formulations such as emulsions 
and gels
24-25
. 
Nanoemulsion can reduce the frequency and dosage 
of injections throughout the drug therapy period as this 
emulsion guarantee the release of drugs in a sustained and 
controlled mode over long periods of time. Additionally, 
the lack of flocculation, sedimenta- tion and creaming, 
combined with a large surface area and free energy, offer 
obvious advantages over emulsions of larger particle size, 
for this route of administration
26
. 
Another interesting application, which is 
experiencing an active development, is the use of 
nanoemulsion formulations, for controlled drug delivery 
and targeting
27
. Because of their submicron size, they can 
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easily be targeted to the tumor area. The development of 
magnetic nanoemulsions is an innovative approach for 
cancer therapy. 
A vaccine carrier system using nanoemulsions is 
currently being researched. This medication delivery 
system uses nanotechnology to vaccinate against human 
immunode- ficiency virus (HIV). There is recent evidence 
that HIV can infect the mucosal immune system. 
Therefore, developing mucosal immunity through the use 
of nanoe- mulsions may become very important in the 
future fight against HIV
28
. The oil-based emulsion is 
administered in the nose, as opposed to traditional vaccine 
routes. Research is demonstrating that genital mucosa 
immunity may be attained with vaccines that are 
administered into the nasal mucosa
29
. 
Until now, the submicron emulsion system has not 
yet been fully exploited for pulmonary drug delivery. 
Nebulization of submicron emulsions will be a new and 
upcoming research area. However, extensive studies are 
required for the successful formulation of inhalable 
submicron emulsions due to possible adverse effects of 
surfactants and oils on lung alveoli function (adverse 
interactions with lung surfactant). 
Pickering Emulsions 
Lipid based emulsions stabilized by solid particles 
such as calcium carbonate, latex, silica, clays, titanium 
dioxide are known as pickering emulsions. Recently, there 
is an increasing interest in pickering emulsions because 
they open new avenues of emulsion stabilization. Solid 
particles added, will bind to the surface of the interface and 
prevent the droplets from coalescing thus making emulsion 
more stable. Properties such as hydrophobicity, shape, and 
size of the particle can have an effect on the stability of the 
emulsion
30
. Additionally, it has been demonstrated that the 
stability of the Pickering emulsions can be improved by 
the utilization of amphiphilic particles so-called Janus 
particles due to the higher adsorption energy of the 
particles at the liquid-liquid interface
31
. 
VESICULAR DRUG DELIVERY SYSTEMS  
Newer vesicular systems are evolved every day. Drug 
deliveries as well as other biomedical applications of lipid 
vesicles and other surfactant microstructures are presently 
enjoying huge popularity among a diversity of researchers 
in several disciplines. Lipid vesicular system includes 
liposome, proliposome, phytosome, transfersome, 
ethosome, archaeosome, vesosome, niosome.  
Liposomes
32
 
Liposomes were discovered in the early 1960‘s by 
Bangham and colleagues and subsequently became the 
most extensively explored drug delivery system. 
Structurally liposomes are concentric bilayered vesicles in 
which as aqueous volume is entirely enclosed by a 
membranous lipid bilayer mainly composed of natural or 
sysnthetic phospholipids. Lipomes are formed when 
phospholipids are hydrated. The most common natural 
phospholipids are phosphatidylcholine (PC). These are 
amphiphillic molecules in which a glycerol bridge links to 
a pair of hydrophobic acyl hydrocarbon chains with a 
hydrophilic polar head group phosphocholine. 
Amphiphillic nature of phospholipids and their analogues 
render them the ability to form closed concentric bilayers 
in the presence of water. Liopsomes are formed when thin 
films of amphiphilic nature are hydrated and stacks of 
liquid crystalline bilayers become fluid and swell. The 
hydrated lipid sheets detach during agitation and self close 
to form large multilamellar vesicles (MLVs). Sonification 
is done to get small unilamellar vesicles (SUVs). Extrusion 
is also done to get large unilamellar vesicles (LUVs). 
Several methods exist for improved loading of drugs using 
pH gradients and potential difference across liposomal 
membranes. The pH gradient is created by preparing 
liposomes with a low pH inside the vesicles followed by 
the addition of the base to the extra liposomal medium. 
Accumulation occurs at the low pH side. So the 
unprotonated form of basic drug can diffuse through the 
bilayer. At the low pH side, the molecules are 
predominately protonated which lowers the concentration 
of drug in the unprotonated form and thus promotes the 
diffusion of more molecules at the low pH side of the 
bilayer. Stealth liposomal technology is designed for the 
intravenous drug delivery. 
Proliposomes
33
 
In order to increase the surface area of dried lipid 
film and to faciliatate hydration, the lipid is dried over a 
finely divided particulate support. These dried lipid coated 
particulates are called pro-liposomes. Pro-liposomes form 
dispersion of MLVs on adding water into them. This 
method overcomes the stability problems of liposomes 
encountered during their storage as dispersion, dry or 
frozen form. It is ideally suited for preparations where the 
drug to be entrapped incorporated into lipid membrane. 
Phytosomes 
Phytosome is a complex between a natural product 
and natural phospholipids, like soy phospholipids. Such a 
complex is obtained by reaction of stoichiometric amounts 
of phospholipids and the substrate in an appropriate 
solvent. On the basis of spectroscopic data it has been 
shown that the main phospholipids-substrate interaction is 
due to the formation of hydrogen bonds between the polar 
head of phospholipids (i.e. phosphate and ammonium 
groups) and the polar functionalities of the substrate. When 
treated with water, phytosomes assumes a micellar shape 
forming liposomal-like structures
34
.  
 
Figure 2: Major difference between liposome and 
phytosome: the molecular organization of the liposome 
(upper segment) versus many individual phytosomes 
(lower segment). 
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Phytosomes provide a new basis for delivery of 
phytoconstituents by improving its bioavailability which is 
attained by reducing the polarity of active substance, 
enhancing their rate and the extent of solubilisation into 
aqueous intestinal fluids and their capacity to cross 
biomembranes. They have been used to deliver liver-
protecting flavonoids because they can be made easily 
bioavailable by phytosomes
35
. 
Transfersomes 
Transfersome is a term which means ―carrying 
body‖, which is originated from ‗transferre‘ a Latin word, 
implying ‗to take across‘, and  ‗soma‘,  a Greek word 
means for a ‗body‘. A lipid particulate delivery system for 
transfersome is an artiﬁcial vesicle designed to be like a 
cell vesicle or a cell engaged in exocytosis, and thus 
suitable for controlled and, potentially targeted, drug 
delivery. Transfersomes are a special type of liposomes, 
consisting of phosphatidylcholine and a surfactant which 
act as an edge activator
36
. 
Transfersomes were developed in order to take the 
advantage of phospholipids vesicles as transdermal drug 
carrier. These self-optimized aggregates, with the ultra 
flexible membrane, are able to deliver the drug 
reproducibly either into or through the skin, depending on 
the choice of administration or application, with high 
efficiency
37
. These vesicular transfersomes are several 
orders of magnitudes more elastic than the standard 
liposomes and thus well suited for the skin penetration. 
Transfersomes overcome the skin penetration difficulty by 
squeezing themselves along the intracellular sealing lipid 
of the stratum corneum. There is provision for this, 
because of the high vesicle deformability, which permits 
the entry due to the mechanical stress of surrounding, in a 
self-adapting manner. Flexibility of transfersomes 
membrane is achieved by mixing suitable surface-active 
components in the proper ratios
38
. The resulting flexibility 
of transfersome membrane minimizes the risk of complete 
vesicle rupture in the skin and allows transfersomes to 
follow the natural water gradient across the epidermis, 
when applied under nonocclusive condition. 
Transfersomes can penetrate the intact stratum corneum 
spontaneously along two routes in the intracellular lipid 
that differ in their bilayers properties
39
. The following 
figure shows possible micro routes for drug penetration 
across human skin intracellular and transcellular
40
. 
Transfersome vesicles can transport molecules that 
are too big to diffuse through skin Eg: systemic delivery of 
therapeutically meaningful amounts of macromolecules, 
such as insulin or interferon
41-42
. Other applications include 
the transport of small molecule drugs which have certain 
physicochemical properties which would otherwise 
prevent them from diffusing across the barrier. Now a day, 
transfersome can be used to target peripheral subcutaneous 
tissue. Topical immunization using cationic transfersomes 
based DNA vaccine offers all the advantages of DNA 
vaccines, and in addition overcome the disadvantages of 
classical invasive methods of vaccination
43
.  
Ethosomes 
Ethosomes are the trivial modification of liposome, a 
well well-known drug delivery service. Being soft, 
malleable lipid vesicles they are used for enhanced 
delivery of active agents. Ethosomal systems are vesicular 
systems composed mainly of phospholipid, ethanol, 
propylene glycol and water
44
. Unlike classic liposomes, 
that are known mainly to deliver drugs to the outer layers 
of skin, ethosomes were shown to enhance permeation 
through the stratum corneum barrier
45-50
. Ethosomes are 
shown to entrap drug molecule with various 
physiochemical characteristics i.e. of hydrophilic, 
lipophilic or amphipilic
51
. 
Archaeosomes 
Archeosomes are archebacteria lipids consisting 
vesicles. They are less sensitive to oxidative stress, high 
temperature, and alkaline pH
52-53
. Archaeosomes are 
nothing but liposomes in 200nm size range, which are 
prepared from ether lipids extracted from various 
Archaeobacteria Archaeosomes (liposomes comprised of 
glycerolipids of Arcaea) are lipid vesicles and their 
membranes are constituted of ether linked isoprenoid 
phytanyl core lipid or purified lipid sub fractions
54-57
. 
Archaeosomes constitute a novel family of liposomes 
made with one or more of the fully saturated bipolar tetra 
ether lipids, which exerts a higher stability in comparison 
with conventional lipids to several conditions such as high 
temperature, alkaline or acidic pH, and presence of 
phospholipases, bile salts and serum media
58
. 
It has been shown that incorporation of polyethylene 
glycol and Coenzyme Q10 into archaeosomes can alter the 
tissue distribution profiles of intravenously administered 
vesicles
59
. It had also reported that intravenous and oral 
delivery of nanometric-sized archaeosomes to an animal 
model was well tolerated with no apparent toxicity. The 
results of these studies are very promising for the 
utilisation of archaeosomes in the encapsulation and 
delivery of different bioactive compounds
60-61
. 
Vesosome 
Vesosome consists of one or more bilayers enclosing 
an aqueous core that contains unilamellar vesicles that 
function as internal compartments which contain the drug 
and which can vary in composition from each other. The 
external bilayer defines the lumen, limits emission of the 
vesicle contents, and protects the vesicle contents from 
degradation due to lipolytic enzymes. Its unique properties 
enable localizeddrug delivery in specific parts of the body 
and extend the duration of drug effect. 
Niosomes
62-64
 
Non ionic surfactant vesicles (NSVs or Niosomes) 
are now widely studied as an alternative to liposomes. 
Non-ionic surfactant vesicle results from self assembly of 
hydrated surfactant monomers. Niosomes are essentially 
non ionic surfactant based multi or unilamellar vesicles in 
which an aqueous solution is entirely enclosed by a 
membrane resulted from the organization of surfactant 
macromolecules as bilayers. Ether injection, hand shaking 
method, sonification, reverse phase evaporation, aqueous 
dispersion and extrusion are various methods of 
preparation of niosomes. 
LIPID PARTICULATE SYSTEMS 
In recent decades, lipids of biocompatible 
microparticles and nanoparticles have evolved as potential 
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polymers carriers. Their unique size dependant properties 
and the ability to fit in drug into nanocarriers, evolve them 
as potential drug delivery systems. Some advantageous 
features of lipid particulate systems include:  
 Physiologically compatible and physicochemically 
stable carrier systems  
 Controlled drug release  
 Higher levels of drug targeting  
 Allows large-scale production at a relatively low 
production cost  
 Protection of incorporated active compounds against 
degradation  
 Solid matrix is composed of well tolerated lipids.  
 Uncomplicated scale-up.  
Lipid microparticles  
Polymeric microspheres have been tested 
successfully as sustained release drug delivery system 
however their safety still remains uncertain which leads to 
the development of solid lipid microparticles (SLMs)
65
. 
Lipid microspheres known as lipospheres are composed of 
a solid hydrophobic fat core (triglycerides) stabilized by a 
layer of phospholipid molecules embedded on their 
surface. These fat based encapsulation system contain the 
bioactive compound in the internal core, dissolved or 
dispersed in the solid fat matrix
66
.  
Lipid nanoparticles  
Polymeric nanoparticles have many disadvantages 
like cytotoxicity of the polymers after internalization in to 
the cell as well as its difficulty in large scale production 
which leads to the use of physiological lipids or lipids as 
drug carriers. Solid lipid nanoparticles (SLNs), 
nanostructure lipid carriers (NLC) and lipid drug 
conjugates (LDC) are innovative carrier systems which 
overcome the above associated problems as well.  
The SLNs are sub-micron colloidal carriers which are 
composed of physiological lipid, dispersed in water or in 
an aqueous surfactant solution. Advantages of SLN are the 
use of physiological lipids, the avoidance of organic 
solvents, a potential wide application spectrum (dermal, 
per oral, intravenous) and the high pressure 
homogenization as an established production method
67
. 
Potential disadvantages such as poor drug loading 
capacity, their particle growing, unpredictable gelation 
tendency, drug expulsion after polymeric transition during 
storage and relatively high water content of the dispersions 
(70-99.9%) have been observed
68-69
.  
Nano structured lipid carriers (NLC) are mixtures of 
solid and fluid lipids, the fluid lipid phase is reported to be 
embedded into the solid lipid matrix or to be localized at 
the surface of solid platelets and the surfactant layer
70
. 
NLC system minimizes or avoids the following 
disadvantages of SLNs like low drug loading capacity, 
drug expulsion during storage and high water content
71
.  
Another major problem of SLN is the low capacity to 
load hydrophilic drugs due to partitioning effects during 
the production process. Thus only highly potent low dose 
hydrophilic drugs may be suitably incorporated in the solid 
lipid matrix
72
. In order to overcome this limitation, the so 
called lipid drug conjugate (LDC) nanoparticles with drug 
loading capacities of up to 33% have been developed
73
. 
Many applications like drugs with irritant effects like 
tretinoin turns out to be less irritating if applied when 
encapsulated within SLN
74
. Lipid nanoparticles can be 
used to improve the bioavailability of drugs, e.g. 
cyclosporine A60, clozapine, to improve the stability of 
chemically labile hydrophobic antioxidants like retinol, 
CoQ10, alpha-lipoic acid, beta-carotene and alpha-
tocopherol and to obtain sustained release of lipophilic 
drugs like camptothecin
75-76
. Idarubicin-loaded SLN acted 
as a prolonged release system after duodenal 
administration to rats
77
.  
CONCLUSION 
Lipid based drug delivery systems, a physiologically well-
tolerated class of formulations, provide a vast array of 
possibilities to formulate and potentially increase the 
bioavailability of an ever-growing number of poorly 
soluble drugs. In recent years, progressive elucidation of 
the various mechanisms through which lipids can increase 
bioavailability – a unique combination of solubilisation, 
dispersion or encapsulation, and stimulation of the 
digestive process, potential inhibition of receptor-mediated 
efflux or pre-systemic metabolism, or (even if poorly 
understood), passage through the lymphatic system – have 
all contributed, and will continue to contribute to a greater 
number of products in preclinical and clinical 
development, and in the market. On the way of conclusion, 
the prospect of these delivery systems looks promising. 
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